Proactive Investors - Run By Investors For Investors

CB2 Insights names artificial intelligence pioneer as senior adviser to data insights division

There is a lack of medical cannabis data, according to the company, which is aiming to be a front-runner in filling demand
Cannabis
The company operates in the medical cannabis data space

CB2 Insights (CSE:CBII), the medical cannabis-focused data firm, has named artificial intelligence (AI) pioneer Dr Randy Goebel as a senior adviser to its data insights division.

Goebel is a professor of computing science at the University of Alberta and is involved in academic and industrial projects in Europe and Japan. His appointment is aimed at further advancing the the company's predictive-analytics tools and insights capabilities.

READ: CB2 Insights opens new chapter as medical cannabis data supplier begins CSE trading

There is a lack of medical cannabis data, according to the company, which is aiming to be a front-runner in filling demand.

CB2 Insights currently evaluates 65,000 patients annually through its clinic network and handles millions of clinically validated data points to advance understanding of the effectiveness and risks associated with cannabinoid therapy.

"There is no question that there is an urgent need for more robust usable data systems within the medical cannabis space," said Dr. Goebel.  "I am excited to help CB2 Insights advance its platform to better exploit the critical data it ingests every day and explore cannabinoid therapy in a way that has not previously been done."

Dr. Goebel will help work on platform architecture and design enhancements to help serve a variety of new stakeholders in the company such as regulatory bodies, government agencies, researchers and pharma firms.

Meanwhile, on Wednesday, in a separate statement, the company announced it had completed the conversion of 100% of outstanding convertible senior secured debentures entered into between May and September 2017, retiring $959,000 of principal, accrued interest and outstanding fees by issuing more than 7.5 million common shares

Contact Giles at [email protected]

Follow him on Twitter @Gile74

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CBII profile View Profile

CB2 Insights Timeline

Related Articles

A visual representation of a drug candidate working in a dog
January 28 2019
The company has reaffirmed its upcoming milestones as it confirmed December quarter achievements.
Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry
cannabis facility
January 23 2019
The company will capitalize on the need for indoor-grown, pharmaceutical-grade cannabis
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use